Evommune Reports Phase 2a POC Signal for EVO301 in Atopic Dermatitis

Evommune reported Phase 2a proof-of-concept data for EVO301 showing a therapeutic signal at Week 12 for moderate-to-severe atopic dermatitis. The drug demonstrated safety in line with placebo. The company plans a global Phase 2b trial with a subcutaneous formulation beginning mid-2027.